Trial Profile
Intravitreal Aflibercept in Patients With Retinal Pigment Epithelial Detachment (PED) Secondary to Age Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Planned End Date changed from 1 May 2018 to 1 Apr 2019.
- 19 Dec 2017 New trial record